The global breast biopsy market size was valued at USD 2.83 billion in 2025 and is projected to grow from USD 3.14 billion in 2026 to USD 7.12 billion by 2034, registering a CAGR of 10.8% during the forecast period from 2026 to 2034. North America dominated the breast biopsy market with a market share of 38.6% in 2025.
A breast biopsy is a diagnostic procedure used to remove a small sample of breast tissue or cells for laboratory examination to determine whether an abnormal area is benign or cancerous. It may be performed using fine-needle aspiration, core needle biopsy, vacuum-assisted biopsy, or surgical methods. Breast biopsies play an important role in confirming breast cancer diagnoses and guiding appropriate treatment decisions.
Download a Free Sample To learn more about this report,
Growing Adoption of Contrast-Enhanced Mammography-Guided Biopsy
The breast biopsy market is expanding beyond conventional stereotactic and ultrasound guidance toward contrast-enhanced mammography-guided procedures. This approach helps physicians target suspicious enhancing lesions that may be difficult to identify using standard mammographic views or ultrasound, potentially allowing diagnosis within the same imaging pathway in which the abnormality was detected. Broader availability can reduce dependence on more resource-intensive MRI-guided procedures for selected patients. Contrast-guided tissue sampling is therefore becoming an important part of breast biopsy market trends.
In April 2025, GE HealthCare received FDA 510(k) clearance for its Serena Bright Contrast-Guided Biopsy solution. The system allows breast biopsy targeting using contrast-enhanced mammography and is designed to operate with the company's Senographe Pristina platform, which can complete contrast-enhanced examinations in less than 7 minutes.
Increasing Development of Robotic Systems for Breast Biopsy Procedures
Robotic assistance is emerging as a new direction for breast biopsy by enabling controlled positioning of biopsy instruments using imaging information and automated navigation. Such systems can potentially improve targeting consistency while reducing repetitive manual positioning during image-guided interventions. Robotic platforms may become particularly useful as breast imaging produces increasingly precise three-dimensional information about small lesions. This technology development is expanding the breast biopsy industry toward more automated interventional workflows.
In November 2025, MURAB Technologies advanced its robotic breast biopsy platform after securing EUR 8 million in financing. The system combines ultrasound imaging, robotics, and tissue characterization technologies to support more precise breast-biopsy procedures.
Expansion of Breast Cancer Screening Increases Diagnostic Follow-Up
Breast screening identifies suspicious masses, calcifications, and other abnormalities that cannot always be classified conclusively through imaging alone. Patients with concerning findings may subsequently require tissue sampling to determine whether a lesion is benign or malignant. As screening programs reach more women and imaging technologies detect smaller abnormalities, the number of findings requiring pathological confirmation can increase. Broader screening participation is therefore strengthening breast biopsy market demand.
In September 2025, NHS England reported that more than 2.1 million women had undergone breast screening during the previous year. Approximately 18,000 cancers were detected through the program, demonstrating the large diagnostic pathway created by population-level breast screening.
Procedure-Related Complications Can Reduce Patient Acceptance
Although needle biopsy is less invasive than surgical excision, patients can still experience bleeding, bruising, hematoma, pain, infection, or other complications following tissue sampling. Concern about discomfort and procedural risks can create anxiety and may influence acceptance of repeat biopsies, particularly when imaging findings have a relatively low probability of malignancy. Providers must balance adequate tissue acquisition against minimizing trauma. These procedural concerns can consequently restrain breast biopsy market growth.
In May 2025, Hologic expanded clinical education around its Brevera breast biopsy system, which can acquire and image tissue samples in approximately 10 seconds per specimen, illustrating ongoing efforts to shorten procedures and limit the intervention burden associated with tissue acquisition.
Expansion of Liquid Biopsy for Breast Cancer Assessment
Blood-based tumor analysis creates a distinct opportunity to complement tissue biopsy by detecting circulating tumor DNA and other cancer-associated biomarkers through a blood sample. Liquid biopsy can potentially support molecular profiling when obtaining additional tissue is difficult and can allow repeated sampling during treatment without another invasive procedure. Wider clinical validation could therefore create a new diagnostic pathway alongside conventional breast tissue sampling. Companies developing these tests can increase breast biopsy market share through minimally invasive molecular assessment.
In October 2025, Guardant Health reported expanded breast cancer applications for its Guardant360 liquid biopsy platform, which evaluates more than 70 cancer-related genes from a blood sample and supports genomic profiling for patients with advanced solid tumors.
Obtaining Adequate Tissue From Small or Difficult-to-Reach Lesions
Breast imaging is increasingly capable of identifying very small abnormalities, but accurate diagnosis still depends on retrieving representative tissue from the correct location. Lesions positioned close to the chest wall, implants, skin, or other sensitive structures can make needle placement more difficult, while inadequate samples may require another procedure. Biopsy systems must therefore combine precise targeting with sufficient tissue acquisition and patient safety. Reliable sampling of technically difficult lesions remains a major challenge as breast biopsy market size expands alongside increasingly sensitive imaging.
In February 2026, Merit Medical Systems expanded its breast-biopsy portfolio with additional localization and tissue-access technologies designed for challenging lesions. Selected devices support targeting depths of more than 10 cm, helping clinicians access abnormalities located deeper within breast tissue.
Biopsy Needles Segment Dominated the Market with 29.4% Share in 2025
The biopsy needles segment dominated the global breast biopsy market with a 29.4% market share in 2025, valued at USD 0.83 billion. The segment's dominance is driven by the widespread use of biopsy needles for obtaining breast tissue samples, their suitability for minimally invasive procedures, and their extensive application in breast cancer diagnosis. Growing demand for early and accurate detection continues to support adoption.
The biopsy forceps, guidance systems, needle-based biopsy guns, localization wires, and other guidance techniques continue to support breast biopsy procedures by improving tissue collection, lesion localization, and procedural accuracy. Technological advancements in biopsy devices are further supporting their adoption.
Request Customizationto receive a tailored report.
The liquid breast biopsy segment is Projected to Register the Fastest Growth at a CAGR of 10.36%
The liquid breast biopsy segment is projected to register the fastest growth at a CAGR of 10.36% during the forecast period. Growing interest in minimally invasive cancer diagnostics, advances in circulating biomarker analysis, and increasing research into blood-based approaches for cancer detection and monitoring are supporting segment growth.
The fine-needle aspiration biopsy, core needle biopsy, vacuum-assisted breast biopsy, excisional and incisional breast biopsy, and open surgical breast biopsy segments continue to play important roles in breast cancer diagnosis. Their use varies according to lesion characteristics, clinical requirements, and the amount of tissue required for analysis.
The image-guided biopsy segment dominated the Market with 88.3% Share in 2025
The image-guided biopsy segment dominated the global breast biopsy market with an 88.3% market share in 2025, valued at USD 2.50 billion. The segment's leadership is driven by the widespread use of imaging technologies to accurately locate suspicious breast abnormalities and guide tissue sampling. Greater procedural precision and the ability to target difficult-to-detect lesions continue to support its strong adoption.
The liquid biopsy segment continues to gain attention as a minimally invasive approach for identifying and monitoring cancer-related biomarkers. Ongoing developments in molecular diagnostics and precision oncology are expanding the potential role of liquid biopsy in breast cancer management.
The recurrence monitoring segment is Projected to Register the Fastest Growth at a CAGR of 8.49%
The recurrence monitoring segment is projected to register the fastest growth at a CAGR of 8.49% during the forecast period. Increasing emphasis on post-treatment surveillance, early identification of cancer recurrence, and personalized follow-up strategies is driving demand for advanced biopsy and diagnostic approaches for monitoring breast cancer patients.
The early cancer screening, therapy selection, and treatment monitoring segments continue to generate strong demand as breast biopsy plays an important role throughout cancer diagnosis and treatment planning. Growing emphasis on early detection and personalized treatment decisions is supporting these applications.
Hospitals and Surgical Centers Segment Dominated the Market with 51.6% Share in 2025
The hospitals and surgical centers segment dominated the global breast biopsy market with a 51.6% market share in 2025, valued at USD 1.46 billion. The segment's dominance is driven by access to advanced diagnostic equipment, skilled medical professionals, surgical capabilities, and comprehensive breast cancer care services. Their ability to manage complex diagnostic procedures further supports their leading position.
The breast care centers and imaging and diagnostic centers continue to witness steady demand due to their specialized diagnostic capabilities and focus on breast health services. Increasing availability of dedicated breast imaging and biopsy facilities is supporting their role in early diagnosis and patient management.
Speak to an Analystto discuss market opportunities.
North America's breast biopsy market accounted for 38.6% of the global market, reaching USD 1.09 billion in 2025, and is projected to grow at a CAGR of 6.91% during the forecast period. Market growth is driven by widespread breast cancer screening, increasing awareness of early diagnosis, strong healthcare infrastructure, and growing adoption of minimally invasive image-guided biopsy procedures and advanced diagnostic technologies.
The United States represents the largest market in North America. Extensive breast cancer screening programs, strong availability of advanced imaging and biopsy technologies, increasing use of core needle and vacuum-assisted biopsy procedures, and established diagnostic infrastructure continue to support market growth.
Increasing breast cancer screening, growing awareness of early disease detection, expanding availability of image-guided biopsy procedures, and improvements in diagnostic healthcare infrastructure continue to support steady market development.
Unlock Regional Insightsto access country-level data, & regional trends.
The European breast biopsy market accounted for 28.4% of the global market, reaching USD 0.80 billion in 2025, and is expected to register a CAGR of 6.74% during the forecast period. Established breast cancer screening programs, increasing adoption of minimally invasive biopsy procedures, growing use of advanced imaging technologies, and rising emphasis on early cancer diagnosis continue to support regional market expansion.
Germany represents a major European market. Established cancer screening infrastructure, increasing utilization of image-guided breast biopsy, availability of advanced diagnostic technologies, and growing emphasis on accurate and early breast cancer diagnosis continue to support market growth.
Organized breast screening programs, increasing demand for minimally invasive diagnostic procedures, growing adoption of advanced breast imaging technologies, and continued focus on early cancer detection support market development.
The Asia Pacific breast biopsy market accounted for 22.7% of the global market, reaching USD 0.64 billion in 2025, and is projected to register a CAGR of 9.18% during the forecast period. The region represents the fastest-growing market, supported by increasing breast cancer awareness, improving access to diagnostic services, expanding healthcare infrastructure, rising screening participation, and growing adoption of advanced biopsy and imaging technologies.
China represents a major market within the Asia Pacific. Expanding cancer screening initiatives, increasing awareness of breast cancer, improving hospital diagnostic capabilities, and growing adoption of minimally invasive biopsy technologies continue to drive market expansion.
Increasing awareness of breast cancer, expansion of specialized diagnostic centers, improving access to mammography and image-guided procedures, and rising investment in cancer diagnosis and treatment infrastructure continue to strengthen market growth.
Latin America's breast biopsy market accounted for 6.1% of the global market, reaching USD 0.17 billion in 2025, and is expected to grow at a CAGR of 7.36% during the forecast period. Improving access to breast cancer screening, increasing awareness of early diagnosis, expanding private healthcare infrastructure, and rising availability of modern biopsy technologies continue to support regional market development.
Brazil represents a major regional market. Increasing breast cancer screening, expanding diagnostic infrastructure, growing availability of specialized cancer centers, and rising adoption of image-guided biopsy procedures continue to create market opportunities.
The Middle East & Africa breast biopsy market accounted for 4.2% of the global market, reaching USD 0.12 billion in 2025, and is anticipated to grow at a CAGR of 6.89% during the forecast period. Increasing awareness of breast cancer, improving diagnostic capabilities, expanding healthcare infrastructure, and growing investments in specialized oncology and women's health services continue to support regional market expansion.
Increasing investment in cancer care infrastructure, growing breast cancer awareness and screening initiatives, expanding availability of advanced imaging systems, and improving access to specialized diagnostic services continue to support market development.
Growing awareness of early breast cancer detection, improving access to diagnostic services, expanding oncology facilities, and increasing availability of minimally invasive biopsy procedures continue to support steady market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Artificial Lung Market Size, Share, Growth, Analysis, 2034
Bronchoscopes Market Size, Share, Growth, Analysis, Report, 2034
Aesthetic Threads Market Size, Share, Growth, Forecast, 2034
Middle East And Africa Diabetes Devices Market Size and Forecast 2034
Bladder Scanners Market Size, Share, Growth, Forecast, 2034
Japan Dialyzer Market Size, Top Share, Demand And Forecast to 2034
We are featured on:
sales@straitsresearch.com